Torley Helen sold $369K of HALO
Torley Helen (PRESIDENT AND CEO) sold 5,401 shares of HALOZYME THERAPEUTICS, INC. (HALO) at $68.35 ($0.37M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a datapoint on management’s share sales, but the pre-arranged 10b5-1 plan suggests the timing was predetermined rather than reactive to new information.
Market read
Traders may briefly reassess sentiment/positioning around insider activity, but there is no new fundamental catalyst in the filing.
What to watch
Check whether this sale is part of a larger scheduled program size/frequency and whether other insiders simultaneously transact; single Form 4 prints can be noisy.
Background
The article is an SEC Form 4 insider transaction disclosure for Halozyme Therapeutics (HALO).
Ticker impact
CEO Torley Helen sold 5,401 HALO shares in an open-market transaction under a pre-arranged 10b5-1 plan, per Form 4 filed June 3.
Low likelihood of sustained price move solely from this Form 4; any reaction would be short-lived and sentiment-driven.
The filing is a routine insider transaction disclosure with explicit 10b5-1 pre-arrangement; no new operational or financial catalyst is provided.
Market effects
Minimal—this is company-specific insider transaction disclosure without sector-wide new information.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s risk management or valuation views; monitor for clustering of sales.
Key entities
- public_companyHALO
Issuer of the reported insider transaction (Halozyme Therapeutics, Inc.).
- insiderTorley Helen
President and CEO who sold shares under a 10b5-1 pre-arranged plan.
